Ship2B promotes economic and social enterprises profitability that manages an impact investment vehicle. Ship2B foundation is boosted by big business leaders with the intention of promoting economic and social enterprises profitability, also managing an impact investment vehicle.

Ship2B

Biozell Ventures was created as an investment company focused on startups and scaleups in biotech, pharma and healthcare.

Biozell Ventures

Lanzadera Accelerator provides entrepreneurial solutions for entrepreneurs to implement robust business models. It invites individuals and organizations with innovative business projects and offers them educational, economic, and structural resources in order to implement their projects.  Lanzadera Accelerator was founded in 2013.

Lanzadera Accelerator

Angels Capital philosophy is to find and support at 1 able to lead a project. Their goal is to support the entrepreneurial, helping to create new businesses, help grow their business sector, generate employment and create wealth.

Angels Capital

EDEM Business School aims to train businessmen, managers, and entrepreneurs and the promotion of leadership and entrepreneurial spirit. The School trains businessmen, managers, engineers, and entrepreneurs of today and of the future with the same objective: to promote the entrepreneurial spirit, a culture of effort and leadership, and to become a source of talent for society. EDEM was established in 2002 as a non-profit, private Foundation and was created in the environment of the Valencian Association of Entrepreneurs (AVE) and its headquarters is located in Valencia, Valencia.

EDEM Business School

YSOTOPE THERANOSTICS

YSOTOPE uses specific ligands to design co-diagnostic radiotracers to monitor CAR-T cells inside the patient’s body. YSOTOPE is a Spanish company founded in 2022 by a team with experience in deeptech entrepreneurship and radiochemistry. The loss of CAR-T in blood is a problem for oncologists making them more difficult to personalize the treatment. Molecular imaging is a non-invasive solution for providing information about CAR-T therapy to oncologists.

Ysotope Theranostics is a company focused on improving cancer treatments through the use of high-precision medical imaging. Their technology aims to enhance oncological therapies by leveraging advanced imaging techniques. Ysotope Theranostics specializes in developing innovative solutions to tackle cancer, one of the leading causes of death worldwide. The company's core mission is to revolutionize cancer care through advanced imaging and precision medicine approaches.

Cómo mejorar la terapia contra el cáncer: el proyecto de una start con ADN valenciano

Radioactive materials open up new pathways in patient treatment and medication

Radiopharmaceuticals

YSOTOPE Theranostics

Ysotope Theranostics is a company focused on improving cancer treatments through the use of high-precision medical imaging. Their technology aims to enhance oncological therapies by leveraging advanced imaging techniques. Ysotope Theranostics specializes in developing innovative solutions to tackle cancer, one of the leading causes of death worldwide. The company's core mission is to revolutionize cancer care through advanced imaging and precision medicine approaches.

Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, developed the first radioactive diagnostic agent approved by the US Food and Drug Administration (FDA) for imaging tau neurofibrillary tangles on positron emission tomography (PET) scans. The F-18 flortaucipir tracer, marketed under the name Tauvid, helps clinicians estimate the density and distribution of tau tangles in the brains of adults with cognitive impairment being evaluated for Alzheimer's disease.
Tauvid works by binding to tau proteins that form neurofibrillary tangles, which are a hallmark of Alzheimer's disease along with amyloid plaques. Previously, doctors could only diagnose Alzheimer's neuropathologically by identifying both plaques and tangles in the brain after death. With Tauvid, physicians can now visualize and assess tau pathology in living patients through PET imaging.
The FDA's approval of Tauvid in May 2020 was supported by two clinical studies evaluating the agent's safety and effectiveness. These studies demonstrated that readers interpreting Tauvid PET scans had a high probability of accurately detecting tau pathology and an average-to-high probability of correctly identifying patients without tau pathology.

Avid Radiopharmaceuticals

Trevarx is a biomedical company focused on developing radiopharmaceutical technologies to combat breast, ovarian, and prostate cancer. The company specializes in small molecule radiopharmaceuticals, offering a unique theranostic solution. Trevarx's approach combines therapeutic and diagnostic capabilities, potentially enhancing cancer treatment efficacy. The company leverages its expertise in scientific research and multi-center trials to advance its radiopharmaceutical technologies. Trevarx's business model includes providing support for multi-center trials, regulatory assistance, and GMP (Good Manufacturing Practice) manufacturing. These services aim to accelerate the commercialization process of their radiopharmaceutical technologies. The company's team comprises experts with extensive experience in the field, positioning Trevarx to efficiently develop and bring its solutions to market.

Trevarx Biomedical

Alpha Source is a company that manufactures and supplies alpha radiation sources, primarily composite alpha sources containing Pu-239, Am-241, and Cm-244 radionuclides electroplated onto platinum or platinum-clad nickel foils. These sources are designed for alpha spectroscopy systems, providing alpha particles in the energy range of approximately 5100 to 5800 keV with line widths typically less than 20 keV FWHM. This wide energy range allows for valid energy calibration of most alpha-emitting nuclides. Alpha Source offers its composite alpha sources in three configurations: A-1, A-2, and PM. The sources are uncovered and have an active area of 5.0 mm. When purchased as NIST traceable standards, the sources can also be used to determine detector efficiencies for alpha particles, with total and individual activities provided on the Certificate of Calibration.
In addition to its core alpha source product line, Alpha Source also provides nationwide service for extending the life of ultrasound imaging equipment through preventative maintenance and quality replacement parts. The company offers high-quality replacement parts for biomedical equipment, along with value-added services to streamline supply chain operations.
Alpha Source has over 30 years of expertise in manufacturing and sourcing high-quality medical replacement battery packs, offering solutions that optimize battery life and costs for healthcare facilities.

Alpha Source

Ionetix is a cyclotron technology and isotope manufacturing company based in the US. It developed the world's first commercial compact superconducting cyclotron, the ION-12SC, which is used to produce N-13 Ammonia, a highly accurate Positron Emission Tomography (PET) imaging agent for detecting Coronary Artery Disease (CAD). The company's proprietary cyclotron technology platform enables access to scarce radioisotopes used for diagnostic and therapeutic radiopharmaceuticals.
Ionetix's cyclotrons can produce high-purity alpha-emitting radionuclides like Actinium-225 (Ac-225) and Astatine-211 (At-211), which are utilized in targeted alpha therapies for cancer treatment. In April 2023, the company successfully produced Astatine-211 at its new Alpha Isotope Manufacturing facility in Lansing, Michigan, using a 30 MeV cyclotron. This facility is dedicated exclusively to producing alpha-emitting radionuclides via cyclotrons. In June 2024, Ionetix announced the successful production of Actinium-225, marking a pivotal milestone as the first commercial cyclotron-produced Ac-225.
Ionetix's business model involves establishing a network of ION-12SC cyclotrons installed on or near the campuses of PET programs across the US. The company covers the costs related to installation and operation, making N-13 Ammonia available to providers through a pay-by-the-dose model, ensuring accessibility and affordability. Ionetix also provides N-13, F-18, and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and "white glove" distribution logistics, enabling global access to these imaging agents and targeted radiotherapies.

Ionetix

Therapeia GmbH & Co. KG is a German specialist company focused on developing diagnostic and therapeutic radiopharmaceuticals to address unmet patient needs. Their lead product candidate, ACD-101, is a family of products for the diagnosis and treatment of malignant glioma (brain cancer). ACD-101 combines several anti-cancer effects within a single molecule, including cytostatic properties, an intrinsic radio-sensitizer effect that enhances the efficacy of external radiation therapy (the current standard treatment), and the ability to be radiolabeled with 131I for intracellular 131I-irradiation ("endo-radiotherapy"), similar to radioiodine therapy used for thyroid cancer.
ACD-101 is actively transported across the intact blood-brain barrier and accumulates in tumor tissue, where it is retained for up to a week. This intratumor accumulation occurs independently of histological tumor type in both low and high-grade gliomas (WHO grades II-IV), allowing for universal therapeutic use regardless of glioma histology. In a rat model, experimental human gliomas were curatively treated for the first time using 131I-ACD-101. This endo-radiotherapy can be combined with conventional external radiotherapy to maximize synergies of different anti-tumor modes of action.

Therapeia GmbH & Co. KG

Companies that use radioactive isotopes to develop medication for the treatment of diseases in patients.

Companies that use radioisotopes to develop solutions for the diagnosis of patients. Solutions are typically synthesized for internal use on patients and are employed in tandem with a diagnostic imaging device to identify disease or causes of diseases.

Companies that produce and supply radioisotopes to pharmaceutical companies creating radiopharmaceuticals.

Companies providing support services to radiopharmaceutical-related companies. These include testing services, research, and training.

Some drug developers use connected medical devices for monitoring treatment administration and drug development

YSOTOPE Theranostics

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless